Send to

Choose Destination
Oncotarget. 2017 Jul 31;8(35):59435-59445. doi: 10.18632/oncotarget.19738. eCollection 2017 Aug 29.

A novel lncRNA, LL22NC03-N64E9.1, represses KLF2 transcription through binding with EZH2 in colorectal cancer.

Lian Y#1,2, Yan C#3, Ding J#4, Xia R5, Ma Z1,4, Hui B1,4, Ji H1,4, Zhou J1,4, Wang K1,4.

Author information

The Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, Fujian, People's Republic of China.
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, Jiangsu, People's Republic of China.
Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, 210000 Jiangsu, People's Republic of China.
Contributed equally


Long noncoding RNAs (lncRNA) have been implicated in variety human cancer but their mechanisms of function are mainly undocumented. In the present study, we investigated lncRNAs alteration that contributed to colorectal cancer (CRC) by utilizing TCGA RNA sequencing data and other publicly available lncRNAs expression profiling data. Here, We screened out the CRC-associated lncRNA LL22NC03-N64E9.1, a key regulator of CRC development and progression. We also revealed that knockdown of LL22NC03-N64E9.1 inhibited cell proliferation, colony formation, tumorigenicity and apoptosis promotion, both in vitro and in vivo. Mechanistically, LL22NC03-N64E9.1 repressed underlying target gene KLF2 transcription through binding to EZH2. Furthermore, rescue experiments revealed that LL22NC03-N64E9.1 oncogenic function may partially depend on repressing KLF2. Taken together, our results suggested that LL22NC03-N64E9.1 confered an oncogenic function in human CRC and may serve as a candidate prognostic biomarker and target for new therapies in this deadly disease.


KLF2; LL22NC03-N64E9.1; colorectal cancer; lncRNA; proliferation

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center